Retinal Dystrophies: Clinical Trials

324 trials for Retinal Dystrophies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

139 completed, 55 recruiting, 45 unknown, 34 active not recruiting. 82 Phase 2, 79 Phase 1, 78 Not applicable, 20 Phase 3, 7 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 282Completed 33, Active not recruiting 14, Recruiting 11, Unknown 11, Terminated 8, Not yet recruiting 4, Enrolling by invitation 1
Phase 179Completed 30, Recruiting 17, Active not recruiting 16, Terminated 6, Unknown 6, Not yet recruiting 3, Enrolling by invitation 1
Not applicable78Completed 41, Unknown 12, Recruiting 9, Withdrawn 5, Active not recruiting 3, Not yet recruiting 3, Terminated 3, Enrolling by invitation 2
Phase 320Completed 7, Active not recruiting 4, Not yet recruiting 3, Terminated 3, Unknown 2, Recruiting 1
Early Phase 17Recruiting 3, Unknown 3, Not yet recruiting 1
Phase 42Completed 1, Unknown 1

Follow Retinal Dystrophies: new trials by email Literature Review of Retinal Dystrophies trials Research Report on Retinal Dystrophies

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Non-invasive Ultrasound Retinal Stimulation for Vision Restoration
Non-invasive ultrasound retinal stimulation Device - Age-Related Macular Degeneration, Retinitis Pigmentosa
Not applicableNot yet recruitingUniversity of Southern California52027-01-102026-01-08
24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
N-acetylcysteine amide, Placebo - Retinitis Pigmentosa (RP), Usher Syndrome
Phase 3Not yet recruitingNacuity Pharmaceuticals, Inc.802026-12-012026-07-01
Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
No intervention, will not receive any active study intervention, Intravitreal Injection of Ultevursen - Retinitis Pigmentosa (RP), Usher Syndrome Type 2
Phase 2Not yet recruitingLaboratoires Thea812026-10-052026-09-01
A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
Placebo, NPI-001 - Retinitis Pigmentosa (RP), Usher Syndrome
Phase 3RecruitingNacuity Pharmaceuticals, Inc.802026-10-012026-10-13
Safety Evaluation Study of Pitavastatin PLGA Nano-particle for Retinitis Pigmentosa
ULREA-PVS-NP - Retinitis Pigmentosa (RP)
Phase 1RecruitingKyushu University212026-10-012026-10-07
Phase I/II Open-Label Trial of UGX202 for Advanced Retinitis Pigmentosa
UGX202 Injection - Retinitis Pigmentosa (RP)
Phase 1Not yet recruitingSuzhou UgeneX Therapeutics Co., Ltd.122026-09-282026-10-02
Natural History Study of Advanced RCD
Eye examinations, Questionnaire - Rod Cone Dystrophy
Not applicableRecruitingSparingVision1002026-09-112026-10-08
9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients
9-cis beta-Carotene-rich extract of Dunaliella alga, Placebo Corn Oil - Retinitis Pigmentosa
Phase 1 / Phase 2Enrolling by invitationSheba Medical Center412026-07-262026-07-27
Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment
Active hf-tRNS., Placebo/sham hf-tRNS - Retinitis Pigmentosa (RP), Rod Cone Dystrophy
Not applicableRecruitingUniversity of Waterloo202026-07-012026-07-07
Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection)
ZM-02 (low dose), ZM-02 (high dose), ZM-02 (selected dose) - Retinitis Pigmentosa (RP)
Phase 1 / Phase 2Not yet recruitingZhongmou Therapeutics212026-06-252026-04-13
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
1.5 x 10^6 UC-MSC + CM, 5 x 10^6 UC-MSC + CM - Retinitis Pigmentosa
Phase 2 / Phase 3Not yet recruitingPT. Prodia Stem Cell Indonesia302026-05-012026-02-25
Long-term Safety of UC-MSC Transplantation in Patients With Retinitis Pigmentosa
Conditioned Medium (CM), Umbilical Cord Mesenchymal Stem Cell (UC-MSC) - Retinitis Pigmentosa
Not yet recruitingPT. Prodia Stem Cell Indonesia182026-05-012026-02-25
Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration
PRIMA Products - Stargardt Disease, Retinitis Pigmentosa (RP)
Not applicableRecruitingScience Corporation52026-04-222026-08-17
Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual Performance
Transcorneal Electrical Stimulation using the OkuStim System - Retinitis Pigmentosa (RP), Usher Syndrome
RecruitingOkuvision GmbH302026-04-202026-05-01
A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
DSP-3077 Retinal Sheet Cohort 1, DSP-3077 Retinal Sheet Cohort 2, DSP-3077 Retinal Sheet Cohort 3 - Retinitis Pigmentosa
Phase 1 / Phase 2RecruitingSumitomo Pharma America, Inc.122026-04-162026-04-17
A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)
Phase 1b/2: Cohort 1 - OCT-980 Tablet, Phase 1b/2: Cohort 2 - OCT-980 Tablet, Phase 1b/2: Cohort 3 - OCT-980 Tablet - Retinitis Pigmentosa
Phase 1 / Phase 2RecruitingOctant, Inc.182026-03-102026-09-24
The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa
Alga Dunaliella Bardawil powder, Placebo:Starch - Retinitis Pigmentosa
Phase 1 / Phase 2Not yet recruitingSheba Medical Center302026-03-012025-10-06
Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)
Retinitis Pigmentosa, Stargardt Macular Dystrophy
RecruitingRay Therapeutics, Inc.252026-02-192026-03-31
Inherited Retinal Diseases: Natural History and Genotype-Phenotype Correlations
No Intervention: Observational Cohort - Retinal Degenerations, Retinitis Pigmentosa (RP)
Not yet recruitingIRCCS San Raffaele2002026-01-012025-12-05
Wide Field OCTA in Ocular Diseases
Age - Related Macular Degeneration (AMD), Diabetic Macular Edema
Not yet recruitingIRCCS San Raffaele2002026-01-012025-12-30

Showing 20 of 324. Sign in to see all of them.

Narrower conditions

Retinitis Pigmentosa (267)  ·  Retinal Degeneration (43)  ·  Cone-Rod Dystrophies (39)  ·  Retinal Diseases (39)  ·  Usher Syndromes (33)  ·  Eye Diseases (32)  ·  Macular Degeneration (31)  ·  Stargardt Disease (21)  ·  Eye Diseases, Hereditary (19)  ·  Vision Disorders (18)  ·  Choroideremia (15)  ·  Glaucoma (14)  ·  Diabetic Retinopathy (12)  ·  Leber Congenital Amaurosis (12)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (306)  ·  Genetic Diseases, Inborn (300)  ·  Eye Diseases (292)  ·  Eye Diseases, Hereditary (288)  ·  Retinal Diseases (285)  ·  Retinal Degeneration (281)  ·  Nervous System Diseases (81)  ·  Pathological Conditions, Signs and Symptoms (73)  ·  Signs and Symptoms (71)  ·  Neurologic Manifestations (67)  ·  Sensation Disorders (58)  ·  Congenital Abnormalities (44)  ·  Abnormalities, Multiple (40)  ·  Vision Disorders (38)

Interventions

salicylhydroxamic acid (5)  ·  Intravitreal Injections (4)  ·  Ciliary Neurotrophic Factor (3)  ·  Docosahexaenoic Acids (3)  ·  Minocycline (3)  ·  Vitamin A (3)  ·  retinol acetate (3)  ·  Acetylcysteine (2)  ·  Culture Media, Conditioned (2)  ·  Genotype (2)  ·  Lutein (2)  ·  Ophthalmic Solutions (2)  ·  Tomography, Optical Coherence (2)  ·  Valproic Acid (2)  ·  Visual Prosthesis (2)

Sponsors

National Eye Institute (NEI) (16)  ·  Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (11)  ·  Johns Hopkins University (8)  ·  Nanoscope Therapeutics Inc. (7)  ·  Second Sight Medical Products (6)  ·  Sheba Medical Center (6)  ·  Ankara Universitesi Teknokent (5)  ·  Columbia University (5)  ·  Laboratoires Thea (5)  ·  Okuvision GmbH (5)  ·  Retina Implant AG (5)  ·  SparingVision (5)  ·  University of Michigan (5)  ·  PYC Therapeutics (4)  ·  QLT Inc. (4)

Countries

United States (139)  ·  France (46)  ·  Germany (36)  ·  United Kingdom (31)  ·  China (20)  ·  Canada (19)  ·  Italy (15)  ·  Australia (14)  ·  Netherlands (13)  ·  Israel (12)  ·  Brazil (9)  ·  Switzerland (8)  ·  Belgium (6)  ·  Turkey (Türkiye) (6)  ·  Austria (5)

Top investigators

Umut Arslan, MD (4)  ·  Dr Samarendra Mohanty (3)  ·  Jennifer Henrick, RN, MS (3)  ·  Mohamed Genead, MD (3)  ·  Rubens C Siqueira, MD,PhD (3)  ·  Sushanta Mallick (3)  ·  Anne-Marie Ripley (2)  ·  Brett G Jeffrey, Ph.D. (2)  ·  Brian P Brooks, M.D. (2)  ·  David Liao, MD (2)  ·  Florian Gekeler, Prof Dr med (2)

Results publications

PMID 32573764, PMID 23049090, PMID 37261916, PMID 22562517, PMID 22761263, PMID 23668681, PMID 24150759, PMID 25812924, PMID 26199618, PMID 26604914, PMID 27857759, PMID 27904503, PMID 28878616, PMID 29940167, PMID 32131056, PMID 32303913, PMID 32343050, PMID 32787913, PMID 35814763, PMID 40547876, PMID 10511047, PMID 11931789, PMID 15302656, PMID 15364708, PMID 15364709, PMID 16759390, PMID 16896916, PMID 17460294, PMID 17591900, PMID 18441371, PMID 18515576, PMID 18772487, PMID 18997096, PMID 19098313, PMID 19365014, PMID 19608533, PMID 19953081, PMID 20169166, PMID 20385935, PMID 20720224, PMID 20881025, PMID 21087953, PMID 21296811, PMID 21467183, PMID 21606598, PMID 21693599, PMID 22105799, PMID 22110067, PMID 22110084, PMID 22244176

NIH funding

2016 (2), 2025 (2), 1UG1EY033293 (1), 2009 (1), 2015 (1), 2017 (1), 2018 (1), R00EY029329 (1), R01AG059613 (1), R01EY022931 (1), R01EY029741 (1), R21DC019458 (1), R21EY023720 (1), R24EY019861 (1), R24EY028758 (1)